DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Morgan Stanley - 3 Raymond James - 2 it's - 2 Robert Ford Aguilar - 1 Aguilar - 1 Lisa Kailai Han - 1 Rachel Vatnsdal - 1 GeoMx - 1
Top related locs:
U.S Europe America Caribbean Argentine Delaware NSTG Mondelez
Top related orgs:
Jazz Pharmaceuticals - 5 CNBC - 2 UBS - 2 Bank of America - 2 JPMorgan - 2 RBC - 2 Tyson Foods - 2 Monday - 1

Search resuls for: "Jazz Pharmaceuticals"


11 mentions found


☆ Monday's analyst calls: Big pharma upgrade, top 'clean tech' play
  + stars: | 2023-11-27 | by ( Lisa Kailai Han Fred Imbert | Lisa Kailai Han | Fred Imbert | ) www.cnbc.com   time to read: +11 min
☆ Here are Tuesday's biggest analyst calls: Apple, Nvidia, Zoom, Amazon, Bowlero, Lululemon & more
  + stars: | 2023-08-22 | by ( Michael Bloom | ) www.cnbc.com   time to read: +6 min
Bank of America reiterates Lululemon as buy Bank of America said it's standing by its buy rating on the stock heading into earnings next week. Bank of America adds Jazz Pharmaceuticals to the US1 list Bank of America added the pharmaceutical company to its top picks list. "We initiate coverage of The Madison Square Garden Entertainment Co. (MSGE) with a Buy rating and a 12-month price objective (PO) of $41, implying ~30% potential upside." Bank of America initiates Gulfport Energy as buy Bank of America said the energy company is undervalued. Stifel reiterates Bowlero as buy Stifel said it's standing by its buy rating on the bowling company.
Persons: Morgan Stanley, Lululemon, LULU, Bernstein, Emerson, Raymond James, Apple, it's, Stifel, Jefferies, Goldman Sachs, JEF Organizations: Bank of America, Jazz Pharmaceuticals, Inc, UBS, GXO Logistics, Mobility, RBC, JPMorgan, Emerson, Mizuho, Edison, FOUR, Apple, Nvidia, AppLovin, Garden Entertainment, The, Garden Entertainment Co, Energy, Xcel Energy, Minnesota & Locations: China, The Madison, Minnesota, Minnesota & Colorado
☆ Global stocks are soaring. Analysts love these names — giving one over 80% upside
  + stars: | 2023-06-19 | by ( Weizhen Tan | ) www.cnbc.com   time to read: +2 min
Analysts are still optimistic about some parts of the U.S. market, but some expect international markets to do better this year. The resulting stocks have buy ratings from over 65% of analysts covering them, and average price target upside of at least 30%. Two stocks stood out for their 100% buy rating from analysts and significant potential upside: Coal mining company Yancoal Australia and Hong Kong-listed ESR Group , a real estate services company. German meal kit company Hello Fresh got the highest potential upside from analysts at 82%. U.S. stocks include e-commerce giant MercadoLibre , health insurance firm Humana and pharmaceutical firm Jazz Pharmaceuticals .
Persons: Germany's Dax, Morgan Stanley, J.P, Tai Hui, Tai, Raymond Bridges, Fresh Organizations: Nikkei, Morgan Asset, Bridges Capital, CNBC Pro, CNBC, Vanguard FTSE, Index, Kansai Electric Power, JCR Pharmaceuticals, Humana, Jazz Pharmaceuticals Locations: Europe, U.S, Japan, Asia, Australia, Hong Kong
☆ Cramer's Lightning Round: Novavax is a no-go
  + stars: | 2023-05-31 | by ( Julie Coleman | ) www.cnbc.com   time to read: +1 min
Stock Chart Icon Stock chart icon Jazz Pharmaceuticals' year-to-date stock performance. Stock Chart Icon Stock chart icon ON Semiconductor's year-to-date stock performance. Stock Chart Icon Stock chart icon Novavax's year-to-date stock performance. Stock Chart Icon Stock chart icon Golar LNG's year-to-date stock performance. Stock Chart Icon Stock chart icon Tyson Foods' year-to-date stock performance.
Persons: it's, I'd, You've, Golar, Tyson Organizations: Jazz Pharmaceuticals, Investing, ON, Golar, New Fortress Energy, Tyson Foods Locations: Moderna
☆ Lightning Round: Jim Cramer says 'absolutely not' on buying Tyson Foods
  + stars: | 2023-05-31 | by ( Jim Cramer | ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: Jim Cramer says 'absolutely not' on buying Tyson Foods'Mad Money' host Jim Cramer weighs in on stocks including: Jazz Pharmaceuticals, ON Semiconductor, Novavax, Golar and Tyson Foods.
Persons: Jim Cramer Organizations: Tyson Foods, Jazz Pharmaceuticals, ON Semiconductor
☆ As earnings season winds down, investors turn to Tuesday's debt ceiling meeting
  + stars: | 2023-05-06 | by ( Zev Fima | ) www.cnbc.com   time to read: +12 min
With only a small fraction of the S & P 500 left to report quarterly earnings, investors are now turning their focus to another major hurdle for the markets and economy: the debt ceiling crisis. Earlier this week, we looked back to debt limit crisis of 2011 for potential lessons. The protracted fight ultimately ended in an agreement in early August of that year, but it was a choppy summertime ride for investors. Within the portfolio, Wynn Resorts will report Tuesday, after the closing bell, and Disney will report on Wednesday, after the closing bell. Estee Lauder (EL) and Emerson Electric (EMR) reported earnings before the opening bell.
☆ Jazz Pharma ruling clears U.S. roadblock for rival narcolepsy drug
  + stars: | 2023-02-24 | by ( Blake Brittain | Thomson Reuters | Blake Brittain Reports On Intellectual Property Law | ) www.reuters.com   time to read: +2 min
Feb 24 (Reuters) - A U.S. appeals court ordered Jazz Pharmaceuticals Inc (JAZZP.UL) on Friday to de-list a patent related to its blockbuster narcolepsy drug Xyrem from the U.S. Food and Drug Administration's register of approved medications, in a win for rival drugmaker Avadel CNS Pharmaceuticals Inc. The decision by the U.S. Court of Appeals for the Federal Circuit removes an obstacle for Avadel to sell its own narcolepsy drug Lumryz. Avadel stock was up 4.2% Friday afternoon following the ruling, and Jazz stock was down 1.4%. Jazz sued Avadel for infringing the patent and others in Delaware federal court in 2021, in a lawsuit that is still ongoing. The case is Jazz Pharmaceuticals Inc v. Avadel CNS Pharmaceuticals LLC, U.S. Court of Appeals for the Federal Circuit, No.
☆ Cheap quality stocks offer a smoother ride, according to Trivariate Research
  + stars: | 2023-01-27 | by ( Sarah Min | ) www.cnbc.com   time to read: +2 min
As investors worry about greater market volatility looming in 2023, Trivariate Research offers up some cheap, quality stocks that can be used to play defense. Yet investors struggle to find attractive stocks that are traditionally defensive, according to Trivariate Research. One way investors can find some attractive defensive names would be to look for cheap, quality stocks with low volatility. Pfizer is a defensive stock that is compellingly valued, according to the screen. Meanwhile, Check Point Software Technologies also looks like cheap quality, and was the only technology stock that met Trivariate's criteria, with a 0.63 beta.
☆ U.S. FDA calls for new regulatory framework for use of cannabis compound CBD
  + stars: | 2023-01-26 | by ( ) www.reuters.com   time to read: +2 min
The first-ever cannabis farmer's market in Los Angeles began on July 4 and opens weekly from Friday to Sunday. The health regulator said it would work with Congress to develop a new, cross-agency regulatory framework. The FDA has generally pursued limited enforcement activity regarding CBD, focusing primarily on food and beverage products that make unsubstantiated health claims. "A new regulatory pathway for CBD is needed that balances individuals' desire for access to CBD products with the regulatory oversight needed to manage risks," the agency said. Cannabis products, excluding Jazz Pharmaceuticals Plc's (JAZZ.O) epilepsy drug Epidiolex, are illegal at the federal level in the United States, although some states allow their use.
☆ U.S. FDA weighs regulating cannabis compound CBD in food, supplements - WSJ
  + stars: | 2022-12-27 | by ( ) www.reuters.com   time to read: +1 min
Dec 27 (Reuters) - The U.S. Food and Drug Administration (FDA) is planning to make recommendations on how to regulate the use of popular cannabis compound CBD in food and supplements, the Wall Street Journal reported on Tuesday, citing agency officials. After weighing the evidence on the compound's safety, the FDA will decide within months how to regulate legal cannabis and whether that will require new agency rules or new legislation from Congress, according to the report. Cannabidiol, or CBD, is a non-psychoactive compound derived from cannabis. Cannabis products, excluding Jazz Pharmaceuticals PLC's (JAZZ.O) Epidiolex, are illegal at the federal level in the United States, although some states allow their use. Reporting by Raghav Mahobe in Bengaluru; Editing by Devika SyamnathOur Standards: The Thomson Reuters Trust Principles.
☆ Here are Friday's biggest analyst calls: Apple, Tesla, McDonald's, Netflix, Carvana, Microsoft & more
  + stars: | 2022-12-09 | by ( Michael Bloom | ) www.cnbc.com   time to read: +9 min
Cowen names Costco a top 2023 pick Cowen said Costco is well positioned in a deteriorating macro environment. " Cowen names Caterpillar a top 2023 pick Cowen said the company is well positioned heading into 2023. Cowen names Netflix a top 2023 pick Cowen said it sees free-cash flow ramping up for Netflix in 2023. Morgan Stanley reiterates Apple as overweight Morgan Stanley said investors should take advantage of any weakness and buy the dip in shares of Apple . Morgan Stanley reiterates Lululemon as overweight Morgan Stanley said the company's fundamentals remain strong after its earnings report on Thursday. "
0 next >>
Total: 11